SCHEMBL27226644

SCHEMBL27226644

N#Cc1nccc(N2CCNCC2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 3/20 0.59
▸ HRH4 Q9H3N8 5/20 0.52
▸ PLD1 Q13393 1/20 0.47
▸ GPR119 Q8TDV5 1/20 0.47
▸ CYP1A2 P05177 3/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ HTR3E A5X5Y0 2/20 0.45
▸ HTR3B O95264 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ HTR3A P46098 2/20 0.45
▸ HTR3D Q70Z44 2/20 0.45
▸ HTR3C Q8WXA8 2/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ ROCK1 Q13464 1/20 0.45
▸ CDC42BPB Q9Y5S2 1/20 0.45
▸ PIM1 P11309 1/20 0.44
▸ PRKD1 Q15139 1/20 0.44
▸ PRKD2 Q9BZL6 1/20 0.44
▸ ADRB1 P08588 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30815290 1.00 HRH3 (0.59) HRH3HRH4PLD1GPR119CYP1A2
SCHEMBL15998288 0.85 GPR119 (0.50) HRH3HRH4GPR119HSD17B10ALDH1A1
SCHEMBL29324692 0.83 CXCR4 (0.51) GPR119HSD17B10ALDH1A1ROCK2ROCK1
SCHEMBL27227185 0.81 HRH3 (0.64) HRH3HRH4GPR119CYP1A2HSD17B10
SCHEMBL27226470 0.81 ALDH1A1 (0.54) HRH3HRH4GPR119CYP1A2HSD17B10
SCHEMBL31704451 0.79 GPR119 (0.49) HRH3HRH4GPR119CTSS
SCHEMBL27304519 0.78 GPR119 (0.46) HRH3HRH4GPR119ALDH1A1CTSS
SCHEMBL11042359 0.78 HRH3 (0.65) HRH3HRH4PLD1CYP1A2HSD17B10
SCHEMBL30814858 0.77 GPR119 (0.45) HRH4GPR119CTSS
SCHEMBL30815264 0.77 GPR119 (0.45) HRH4GPR119CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
WO-2025128834-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
US-20240174667-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-05-30 — — US disclosed
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 HRH3 3939/4885HRH4 4563/4885PLD1 612/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 HRH3 3939/4885HRH4 4563/4885PLD1 612/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 HRH3 3939/4885HRH4 4563/4885PLD1 612/4885
US-20240174667-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 HRH3 3939/4885HRH4 4563/4885PLD1 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback